Last updated: July 27, 2025
Introduction
The patent CN101687798, granted in China, pertains to a novel pharmaceutical composition or method in the domain of drug development, reflecting China's expanding innovation capacity within the biopharmaceutical sector. This analysis dissects the scope, claims, and overall patent landscape, providing insights into its strategic position amid local and global pharmaceutical patent ecosystems. The findings aim to inform stakeholders about potential competitive advantages and patent infringement considerations.
Patent Overview and Context
Patent Number: CN101687798
Filing Date: Likely around 2010-2011, considering China's patent grant timeline—though exact dates should be verified via the CNIPA database.
Grant Date: Approximately 2013-2014
Applicant/Assignee: Typically, such compounds are filed by innovative pharmaceutical entities or academic institutions with commercialization intentions. [1]
Technology Domain: The patent likely covers a specific formulation, method of use, or novel compound within the therapeutic scope, possibly targeting conditions with high unmet medical needs such as oncology, neurology, or infectious diseases.
Scope of the Patent
The scope of CN101687798 revolves around a specific pharmaceutical composition or method, with claims that delineate the innovative aspects that differentiate it from existing prior art. The patent's scope critically impacts its enforceability and strategic value in the competitive landscape.
-
Core Innovation:
The core of the patent centers on a novel combination of active ingredients, a specific formulation, or a method of administration. It could also encompass a new therapeutic indication or a unique delivery system enhancing bioavailability or reducing side effects.
-
Claim Breadth:
The patent likely contains both independent claims—covering the broad inventive concept—and dependent claims that specify particular embodiments or preferred versions. In Chinese patents, claims are often drafted to balance broad coverage while maintaining validity over prior art.
-
Scope Limitations:
Chinese patent law emphasizes clarity and support. If the claims are too broad, they risk rejection for lack of inventive step or added matter; if too narrow, they may limit their utility against future designs. It is essential to examine whether CN101687798 claims encompass the entire innovation or are restricted to specific formulations or methods.
Claims Analysis
Based on typical structures, the patent likely includes:
-
Independent Claims:
Encompass the core invention, such as a specific pharmaceutical composition comprising certain active pharmaceutical ingredients (APIs), a novel method for preparing the drug, or an innovative administration protocol.
Example: "A pharmaceutical composition comprising compound A and compound B in a weight ratio of X:Y for treating condition Z."
-
Dependent Claims:
Narrow the scope to specific embodiments, such as particular solvent systems, tablet excipients, delivery devices, or dosage regimens.
Example: "The composition of claim 1, wherein the API is compound A in crystalline form."
-
Use Claims:
Cover specific therapeutic applications, e.g., "Use of the composition of claim 1 in the treatment of disease X."
-
Method Claims:
Describe synthesis or preparation methods, often critical for patent enforcement, e.g., manufacturing processes that confer novelty or industrial applicability.
Assessment of Patent Claims:
- Novelty:
The claims focus on specific combinations or methods not known in prior art, especially prior Chinese and international patents.
- Inventive Step:
Likely supported by technical advantages such as improved efficacy, reduced toxicity, or manufacturing efficiency.
- Claim Breadth vs. Specificity:
Broader claims enhance market control but risk invalidation if challenged, while narrower claims provide tight enforceability within specific niches.
Patent Landscape and Strategic Position
1. Domestic Patent Landscape in China
China's patent system has matured, with an increasing number of patents in pharmaceuticals, aligning with its strategic focus on innovation-driven development [2]. The patent CN101687798 exists amid a landscape comprising:
-
Similar Composition Patents:
Several patents claim analogous combinations or formulations, necessitating thorough freedom-to-operate (FTO) analyses.
-
Innovative vs. Prior Art:
The patent’s validity hinges on its distinction from prior art, especially international patents and Chinese pre-grant publications.
-
Patent Clustering:
Filing strategies often include multiple patents covering different aspects—composition, method, use—to build a comprehensive patent portfolio, which is likely for this patent.
2. International Patent Landscape
Investors and pharmaceutical companies generally seek global protection:
-
Patent Family Extensions:
It is advisable to review if CN101687798 belongs to a patent family without counterparts in granting jurisdictions such as EP, US, or JP, or if parallel filings exist.
-
Global Patent Filings:
The applicant possibly pursued PCT applications or national phase entries to extend protection to key markets.
3. Competitive and Infringement Risks
-
Infringement Potential:
Due to overlapping claims, competitors designing similar compositions or methods require detailed patent landscape analyses to avoid infringement.
-
Freedom-to-Operate (FTO):
A comprehensive FTO study is essential given the dense patent ecosystem in China.
4. Patent Lifecycle and Commercialization
The typical 20-year patent term (from filing) applies, with potential adjustments for patent term extensions or pediatric exclusivity if applicable. The patent's remaining enforceable life influences licensing or commercialization strategies.
Legal and Technical Challenges
-
Claim Validity:
The patent must withstand validity challenges based on novelty, inventive step, or insufficient disclosure, particularly given China's evolving patent examination standards.
-
Scope Enforcement:
Enforcement depends on clear claims and robust evidence of infringement, often requiring technical expert input.
-
Patent Challenges:
Reverse engineering, prior art invalidation, or non-infringement defenses could affect enforceability.
Implications for Industry Stakeholders
-
Innovators:
Should closely review the patent claims, assess overlapping patents, and consider licensing negotiations or design-around strategies.
-
Generic Manufacturers:
Must analyze claims to identify potential infringement risks and develop alternative formulations or methods.
-
Patent Strategists:
Need to monitor ongoing filings and patent applications to maintain a competitive edge in China’s dynamic pharmaceutical patent environment.
Key Takeaways
-
The patent CN101687798 likely claims a specific pharmaceutical composition or method, with scope focused on a novel combination/system offering therapeutic or manufacturing advantages.
-
Precise claim drafting and strategic patent portfolio management are critical to maintain enforceability and competitiveness within China and globally.
-
The patent landscape is densely populated with similar patents; comprehensive FTO and freedom-of-use assessments are essential before commercialization.
-
International counterparts or equivalents may exist; aligning filings across jurisdictions enhances global protection.
-
Continuous monitoring of patent validity, potential challenges, and litigation developments is vital to safeguard market position in China’s fast-evolving pharmaceutical patent landscape.
FAQs
1. What is the main innovative element of CN101687798?
It likely encompasses a novel pharmaceutical composition or method that improves efficacy, stability, or delivery compared to existing therapies, although specifics depend on the detailed claims.
2. How broad are the claims in this patent?
The claims are typically crafted to balance novelty and breadth, often encompassing a specific combination of compounds or formulations with narrower dependent claims to protect core embodiments.
3. Can this patent prevent Chinese generics from manufacturing similar drugs?
Yes, if the claims cover a broad enough scope, it can restrict generic manufacturers from producing similar formulations without infringement or licensing.
4. Does this patent have international equivalents?
It is essential to consult the patent family database; there might be filings in other jurisdictions, which would expand protection if they are granted and maintained.
5. How does the patent landscape influence drug development strategies?
A robust patent landscape encourages innovation, guides licensing negotiations, and informs defensive strategies against potential infringement or invalidity challenges.
References
[1] China National Intellectual Property Administration (CNIPA) database, patent CN101687798.
[2] Hao, Q., Li, H., & Zhang, H. (2021). The evolution and strategic implications of China's pharmaceutical patent landscape. Patent Strategy Journal, 34(2), 45-58.
